Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 17, Issue 3, 2014, Pages 439-446

  Goh, Wayne ^a   Sleptsova Freidrich, Inna ^a   Petrovic, Nenad ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ESOMEPRAZOLE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; PROTON PUMP INHIBITOR;

ACIDIFICATION; ADD ON THERAPY; ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CONTROLLED STUDY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF 10A CELL LINE; MDA MB 468 CELL LINE; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ESOMEPRAZOLE; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; PROTON PUMP INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84908121636     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j34608     Document Type: Article

References (26)

1. Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, Camozzi V: Endocrine therapy of breast cancer. Curr Med Chem, 2011; 18: 513- 522.
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 2007; 13:4429-4434.
3. Ismail-Khan R, Bui MM: A review of triplenegative breast cancer. Cancer Control, 2010; 17:173-176.
4. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol, 1994; 45: 649-656.
5. Thorn CF, Oshiro C, Marsh S, Hernandez- Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics, 2011; 21: 440-446.
6. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxcity: current practice and prospects of prophylaxis. Eur J Heart Fail, 2002; 4: 235-242.
7. Barar J, Omidi Y. Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy. Bioimpacts, 2013; 3: 149-162.
8. +-ATPase as a new strategy against cancer. Cancer Res, 2007; 67: 10627-10630.
9. Rozhin J, Sameni M, Ziegler G, Sloane B. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res, 1994; 54: 6517-6525
10. Xu L, Fukumura D, Jain R: Acidic extracellular pH induces vascular endothelial growth factor (VGEF) in human glioblstoma cells via ERK1/2 MAPK signalling pathway: mechanism of low pH-induced VGEF. J Biol Chem, 2002; 277: 11368-11374.
11. Loeffler D, Juneau P, Heppner G: Natural killercell activity under conditions reflective of tumour micro-environment. Int J Cancer, 1991; 48: 895- 899.
12. Luciani F, Spada M, Demilto A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Lessi E, Parmiani G, Arnacia G, Belardelli F, Fais S: Effect of proton pump inhibitor pretreatment on resistance of solid tumours to cytotoxic drugs. J Natl Cancer Inst, 2004; 96: 1702-1713.
13. Spugnini EP, Citro G, Fais S: Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res, 2010; 29: 44-48.
14. Marelli S, Pace F: Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol, 2012; 6: 423-435.
15. Kendall MJ. Review article: esomeprazole - the first proton pump inhibitor to be developed as an isomer. Aliment Pharmacol Ther, 2003; 17 (Suppl. 1): 1-4.
16. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety. Pharmacol Res, 2009; 59: 135-153
17. Jin HO, Lee YH, Kim HA, Kim EK, Noh WC, Kim YS, Hwang CS, Kim JI, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK: Inhibition of vacuolar H+ ATPase enhances sensitivity to tamoxifen via up-regulation of CHOP in breast cancer cells. Biochem Biophys Res Commun, 2013; 437: 463- 468.
18. Debnath J, Muthuswamy SK, Brugge JS: Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in threedimensional basement membrane cultures. Methods, 2003; 30: 256-268.
19. Szymczak M, Murray M, Petrovic N: Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood, 2008; 111: 3514-3521.
20. Abraham NS: Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol, 2012; 28: 615-620.
21. Ito T, Igarashi H, Jensen RT: Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol, 2013; 29: 650-661.
22. Ferrari S, Perut F, Fagioli F, Brach Del Prever A, Meazza C, Parafioriti A, Picci P, Gambarotti M, Avnet S, Baldini N, Fais S. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. J Transl Med, 2013; 11:268.
23. Spugnini EP, Buglioni S, Carocci F, Francesco M, Vincenzi B, Fanciulli M, Fais S. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med. 2014; 12:225.
24. Spugnini EP, Baldi A, Buglioni S, Carocci F, de Bazzichini GM, Betti G, Pantaleo I, Menicagli F, Citro G, Fais S. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med. 2011; 9:221.
25. Zhang S, Wang Y, Li SJ. Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. Biochem Biophys Res Commun. 2014; 448:424-429.
26. Kraut JA, Helander KG, Helander HF, Iroezi ND, Marcus EA, Sachs G: Detection and localization of H+-K+-ATPase isoforms in human kidney. Am J Physiol Renal Physiol, 2001; 281: F763-F76.